Multiple Factors Suggest Genzyme Still Faces Problems Related To Cerezyme
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech's decontaminated plant has reopened, but FDA plans to re-inspect the facility. In addition, Genzyme had to discard more in-process Cerezyme than expected and a competitor's investigational drug has received clearance for emergency use by FDA.
You may also be interested in...
Continued Genzyme Problems Offer Gaucher Opportunity To Competitors
Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come
Continued Genzyme Problems Offer Gaucher Opportunity To Competitors
Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come
Shire Files NDA For Gaucher Disease Drug With Data Showing Non-Inferiority To Cerezyme
Lower antibody formation could offer significant differentiation from Genzyme's product.